COYA — Coya Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$4.42
-$0.08 (-1.88%)
Coya Therapeutics, Inc. Common Stock (COYA) is a biotechnology company listed on NASDAQ. It is led by Arun Swaminathan Ph.D., based in 5850 San Felipe St., Houston, TX, United States, 77057, with about 8 employees. Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Latest reported COYA revenue for 2025-09-30 was $3.6M. Net income was -$15.5M. Revenue was up 2078.4% from 2025-06-30 to 2025-09-30. COYA currently screens at market cap $118.0M.
Use this COYA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the COYA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the COYA SEC filings page. Lician reads the product cache first so this HTML stays unique to Coya Therapeutics, Inc. Common Stock even when a live quote feed is slow.
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
COYA Key Statistics
Market Cap
$117.99M
Volume
4,321
Previous Close
$5.04
Day Range
$4.83 – $5.03
P/B Ratio
2.40
EPS
-$0.98
Revenue
$3.55M
Net Income
-$14.88M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-40.8%
Profit Margin
-418.7%
Employees
8
COYA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $3.55M | $6.00M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$14.88M | -$7.99M | -$12.24M | -$4.89M |
| EPS (Diluted) | -$0.98 | -$0.79 | -$4.73 | -$1.89 |
Total Assets
$44.35M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$38.34M
Operating Cash Flow
-$10.29M
Free Cash Flow
$0.00
Coya Therapeutics, Inc. Common Stock Company Information
- CEO & Director
- Arun Swaminathan Ph.D.
- Headquarters
- 5850 San Felipe St., Houston, TX, United States, 77057
- Website
- www.coyatherapeutics.com
- Phone
- 800 587 8170
- IPO / Founded
- 2022-12-29
- Sector
- Healthcare
- Industry
- Biotechnology